Overview

Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic dMMR Colorectal Cancers

Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
In this study, the efficacy of pembrolizumab in patients with locally advanced, irresectable dMMR colorectal cancer will be assessed.
Phase:
Phase 2
Details
Lead Sponsor:
The Netherlands Cancer Institute
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Pembrolizumab